4+ day, 2+ hour ago   (230+ words) The Pharma Letter - Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib US clinical-stage biotech Tyra Biosciences (Nasdaq: TYRA) yesterday announced initial results from SURF302, its Phase II study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle…...

4+ day, 4+ hour ago   (209+ words) The Pharma Letter - Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. The round…...

5+ day, 35+ min ago   (228+ words) The Pharma Letter MannKind inks obesity deal with Rose Pharma US biopharma company MannKind Corp (Nasdaq: MNKD) and Rose Pharma today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management....

6+ day, 3+ hour ago   (228+ words) The Pharma Letter - FDA withdraws Krazati's colorectal cancer indication after confirmatory trial miss Bristol Myers Squibb (NYSE: BMY), the US pharma major, has withdrawn the accelerated approval of Krazati (adagrasib) in combination with Erbitux (cetuximab) for KRAS G12C-mutated colorectal cancer…...

1+ week, 4+ hour ago   (239+ words) The Pharma Letter - Positive results for Novo Nordisk STEP Young Phase III trial in children Danish pharma major Novo Nordisk (NOV: N) today announced first results from the STEP Young Phase III trial, evaluating once-weekly semaglutide in combination with a reduced-calorie…...

1+ week, 6+ hour ago   (263+ words) thepharmaletter.com Regulatory round-up: 7 September 2026 Medicines regulators in major international markets have issued a mix of first-in-class approvals, safety reviews, supply and shortage measures, consultations and one authorization suspension over the past week. The latest round-up includes two clearances from…...

2+ week, 4+ day ago   (216+ words) The Pharma Letter - Galen and POA Pharma launch Galsana, a new global brand for rare metabolic diseases Northern Ireland-headquartered pharma company Galen has unveiled Galsana, a new global brand uniting its metabolic disease portfolio with that of Copenhagen-based POA Pharma,…...

2+ week, 6+ day ago   (227+ words) The Pharma Letter - Revier launches with six million euros seed round to develop class IIa HDAC inhibitors for cardiometabolic disease German biotech Revier Therapeutics has launched operations following the close of a six million euros ($6.45 million) seed financing round, the…...

2+ week, 6+ day ago   (254+ words) The Pharma Letter Qiagen appoints Jonathan Pratt as CEO Netherlands-based Qiagen (NYSE: QGEN) announced that Jonathan Pratt has been appointed chief executive (CEO), effective September 1, 2026. He brings to Qiagen more than 25 years of international leadership experience across life sciences, laboratory…...

3+ week, 13+ min ago   (235+ words) The Pharma Letter - Hanmi Pharm inks obesity license deal with Genentech South Korean firm Hanmi Pharm (KRX: 128940) today announced that it has entered into an exclusive licensing agreement with Swiss pharma giant Roche’s (ROG: SIX) subsidiary Genentech, for the development,…...